The India Unlimited 4.0 conference, hosted by the Indian Chemical and Pharmaceutical Association (ICPA), formally opened Tuesday in San Diego, drawing senior representatives from India's top generic drug exporters alongside US healthcare procurement officials navigating an increasingly volatile trade environment. The one-day summit, held at the Marriott Marquis San Diego Marina, was convened against a backdrop of mounting pressure on pharmaceutical supply chains following recent executive orders targeting drug imports.

ICPA officials presented a draft framework titled 'Partnership for Resilience,' calling for expanded long-term supply agreements between Indian manufacturers — including Sun Pharmaceutical, Dr. Reddy's Laboratories, and Cipla — and US hospital group purchasing organisations. The document, circulated to delegates on Tuesday morning, proposes a tiered inventory buffer system designed to insulate American hospitals from short-term tariff shocks while preserving India's competitive pricing advantage in generics.

Representatives from the US Department of Health and Human Services attended as observers, according to sources familiar with the conference agenda, signalling Washington's continued interest in maintaining dialogue with Indian suppliers even as broader trade tensions persist. Industry analysts noted that India supplies roughly 45 percent of generic drugs consumed in the United States, making any disruption to that relationship a direct patient-care concern for American providers.

Dr. Suresh Patel, ICPA's secretary-general, told delegates that the association would submit formal comments to the FDA by end of April regarding proposed changes to abbreviated new drug application review timelines, which Indian manufacturers argue disproportionately affect smaller exporters. He called on both governments to establish a bilateral pharmaceutical working group before the end of the second quarter of 2026.

The conference also featured a panel on biosimilar market access, with speakers from Biocon Biologics and Amneal Pharmaceuticals discussing regulatory pathways for oncology biosimilars pending FDA decisions later this year. Attendees were expected to issue a joint communiqué by Tuesday evening outlining shared priorities for US-India biopharma cooperation through 2028.